Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;34(5):1070-1086.
doi: 10.1007/s12325-017-0532-9. Epub 2017 Apr 20.

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors

Affiliations
Review

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors

Li-Yuan Yu et al. Adv Ther. 2017 May.

Abstract

Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target H+/K+-ATPase, which is located in gastric parietal cells. PPIs are widely used in the treatment of gastric acid-related diseases including peptic ulcer disease, erosive esophagitis and gastroesophageal reflux disease, and so on. These drugs present an excellent safety profile and have become one of the most commonly prescribed drugs in primary and specialty care. Except for gastric acid-related diseases, PPIs can also be used in the treatment of Helicobacter pylori infection, viral infections, respiratory system diseases, cancer and so on. Although PPIs are mainly used short term in patients with peptic ulcer disease, nowadays these drugs are increasingly used long term, and frequently for a lifetime, for instance in patients with typical or atypical symptoms of gastroesophageal reflux disease and in NSAID or aspirin users at risk of gastrotoxicity and related complications including hemorrhage, perforation and gastric outlet obstruction. Long-term use of PPIs may lead to potential adverse effects, such as osteoporotic fracture, renal damage, infection (pneumonia and clostridium difficile infection), rhabdomyolysis, nutritional deficiencies (vitamin B12, magnesium and iron), anemia and thrombocytopenia. In this article, we will review some novel uses of PPIs in other fields and summarize the underlying adverse reactions.

Keywords: Adverse effects; Erosive esophagitis; Gastric acid-related diseases; Gastroenterology; Gastroesophageal reflux disease; Helicobacter pylori infection; Peptic ulcer disease; Proton pump inhibitors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Feng S, Cleary Y, Parrott N, Hu P, Weber C, Wang Y, et al. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway. Eur J Clin Pharmacol. 2015;71(5):617–624. doi: 10.1007/s00228-015-1834-y. - DOI - PubMed
    1. Wang Y, Zhang H, Meng L, Wang M, Yuan H, Ou N, et al. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol. 2010;66(6):563–569. doi: 10.1007/s00228-010-0821-6. - DOI - PubMed
    1. Wang Y, Yuan Y, Meng L, Fan H, Xu J, Zhang H, et al. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. Eur J Clin Pharmacol. 2011;67(1):25–31. doi: 10.1007/s00228-010-0949-4. - DOI - PubMed
    1. Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clinica Chimica Acta. 2008;391(1–2):60–67. doi: 10.1016/j.cca.2008.02.003. - DOI - PMC - PubMed
    1. Abe Y, Sasaki Y, Yagi M, Yaoita T, Nishise S, Ueno Y. Diagnosis and treatment of eosinophilic esophagitis in clinical practice. Clin J Gastroenterol. 2017;10(2):87–102. doi: 10.1007/s12328-017-0725-4. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources